Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial

Annals of Internal Medicine
Maurizio MenichelliAdnan Kastrati

Abstract

The efficacy and safety of a reduced dose of prasugrel versus a standard dose of ticagrelor in elderly patients or those with a low body weight presenting with an acute coronary syndrome (ACS) are unknown. To investigate the effect of an age- and weight-adapted dose of prasugrel versus a standard dose of ticagrelor in patients with ACS. (ClinicalTrials.gov: NCT01944800). Prespecified analysis of the multicenter, randomized ISAR-REACT 5 trial. 23 centers in Germany and Italy. 3997 patients with ACS planned for invasive management. Participants were randomly assigned to receive a standard dose of ticagrelor or prasugrel (reduced dose in the elderly or low-weight group and standard dose in the neither elderly nor low-weight group). The efficacy end point was a composite of death, myocardial infarction, or stroke, and the safety end point was bleeding, both at 12 months. In the elderly or low-weight group, the efficacy end point occurred in 12.7% of patients assigned to receive prasugrel and 14.6% of those assigned to receive ticagrelor (hazard ratio [HR], 0.82 [95% CI, 0.60 to 1.14]); in the neither elderly nor low-weight group, the efficacy end point occurred in 4.8% of patients assigned to receive prasugrel and 7.3% of those ass...Continue Reading

References

May 2, 2007·Circulation·Donald E CutlipUNKNOWN Academic Research Consortium
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Jun 2, 2011·Journal of Clinical Pharmacology·Jeffrey S RiesmeyerWilliam L Macias
Sep 22, 2012·JACC. Cardiovascular Interventions·Stefano SavonittoUNKNOWN Italian Elderly ACS Trial Investigators
Oct 21, 2016·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Cynthia LarmoreGeorge W Vetrovec
Nov 1, 2017·European Heart Journal. Cardiovascular Pharmacotherapy·Leonardo De LucaLeonardo Bolognese
Feb 14, 2018·Heart·Ivan OlierUNKNOWN British Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research
Apr 29, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Ovidio De FilippoMauro Rinaldi
Sep 3, 2019·The New England Journal of Medicine·Stefanie SchüpkeUNKNOWN ISAR-REACT 5 Trial Investigators
Sep 21, 2019·Journal of the American Heart Association·Johannes SchmuckerHarm Wienbergen

❮ Previous
Next ❯

Citations

Mar 12, 2021·Expert Review of Cardiovascular Therapy·Felix VollSalvatore Cassese
Apr 8, 2021·JACC. Cardiovascular Interventions·Piera Capranzano, Dominick J Angiolillo
Jun 17, 2021·Circulation. Cardiovascular Interventions·J J CoughlanSalvatore Cassese
Jun 15, 2021·International Journal of Cardiology·Shqipdona LahuKatharina Mayer
Aug 25, 2021·Nature Reviews. Cardiology·Davide CapodannoDominick J Angiolillo
Sep 21, 2021·European Journal of Clinical Investigation·Gjin NdrepepaAdnan Kastrati

❮ Previous
Next ❯

Software Mentioned

R
R Project for Statistical Computing

Related Concepts

Related Feeds

CZI Human Cell Atlas Seed Network

The aim of the Human Cell Atlas (HCA) is to build reference maps of all human cells in order to enhance our understanding of health and disease. The Seed Networks for the HCA project aims to bring together collaborators with different areas of expertise in order to facilitate the development of the HCA. Find the latest research from members of the HCA Seed Networks here.

Related Papers

The New England Journal of Medicine
Stefanie SchüpkeISAR-REACT 5 Trial Investigators
Nature Reviews. Cardiology
Irene Fernández-Ruiz
Journal of the American College of Cardiology
Christian ValinaAdnan Kastrati
© 2021 Meta ULC. All rights reserved